Association between sex, systemic iron variation and probability of Parkinson's disease

International Journal of Neuroscience

Volumn 126, Issue 4, 2016, Pages 354-360

  Mariani, S ^a   Ventriglia, M ^a   Simonelli, I ^b   Bucossi, S ^b,c   Siotto, M ^d   Donno, S ^e   Vernieri, F ^f   Squitti, R ^a,b  

^a SAN GIOVANNI CALIBITA FATEBENEFRATELLI HOSPITAL   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c CNR   (Italy)

^d IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^e MINISTRY OF HEALTH   (Italy)

^f UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

ceruloplasmin; CP; HFE; iron; Parkinson's disease; PD; transferrin

Indexed keywords

CERULOPLASMIN; COPPER; HFE PROTEIN; IRON; TRANSFERRIN; HEMOCHROMATOSIS PROTEIN; HFE PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATHOGENESIS; SEX DIFFERENCE; ALLELE; BLOOD; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; SEXUAL DEVELOPMENT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; CERULOPLASMIN; COPPER; FEMALE; GENOTYPE; HEMOCHROMATOSIS PROTEIN; HUMANS; IRON; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC; SEX CHARACTERISTICS; TRANSFERRIN;

EID: 84954285006     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2015.1020113     Document Type: Article

References (37)

1. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. New Engl J Med 2003;348:1356-64.
2. Levenson CW. Trace metal regulation of neuronal apoptosis: from genes to behavior. Physiol Behav 2005;86:399-406.
3. Youdim MB, Fridkin M, Zheng H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev 2005;126:317-26.
4. Barnham KJ, Bush AI. Metals in Alzheimer's and Parkinson's diseases. Curr Opin Chem Biol 2008;12:222-8.
5. Castiglioni E, Finazzi D, Goldwurm S, Pezzoli G, Forni G, Girelli D, Maccarinelli F, Poli M, Ferrari M, Cremonesi L, Arosio P. Analysis of nucleotide variations in genes of iron management in patients of Parkinson's disease and other movement disorders. Parkinson's Dis 2010;2011:827693.
6. He Q, Du T, Yu X, Xie A, Song N, Kang Q, Yu J, Tan L, Xie J, Jiang H. DMT1 polymorphism and risk of Parkinson's disease. Neurosci Lett 2011;501:128-31.
7. Rhodes SL, Buchanan DD, Ahmed I, Taylor KD, Loriot MA, Sinsheimer JS, Bronstein JM, Elbaz A, Mellick GD, Rotter JI, Ritz B. Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin. Neurobiology Dis 2014;62:172-8.
8. Kuhn LC. Iron regulatory proteins and their role in controlling iron metabolism. Metallomics 2014;7:232-43.
9. Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, Zeiler B, Bornemann A, Pahnke J, Becker G, Riess O, Berg D. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 2004;63:1912-7.
10. Hochstrasser H, Tomiuk J, Walter U, Behnke S, Spiegel J, Kruger R, Becker G, Riess O, Berg D. Functional relevance of ceruloplasmin mutations in Parkinson's disease. FASEB J 2005;19:1851-3.
11. Hussain RI, Ballard CG, Edwardson JA, Morris CM. Transferrin gene polymorphism in Alzheimer's disease and dementia with Lewy bodies in humans. Neurosci Lett 2002;317:13-6.
12. Mariani S, Ventriglia M, Simonelli I, Donno S, Bucossi S, Vernieri F, Melgari JM, Pasqualetti P, Rossini PM, Squitti R. Fe and Cu do not differ in Parkinson's disease: a replication study plus meta-analysis. Neurobiol Aging 2013;34:632-3.
13. Candore G, Licastro F, Chiappelli M, Franceschi C, Lio D, Rita Balistreri C, Piazza G, Colonna-Romano G, Grimaldi LM, Caruso C. Association between the HFE mutations and unsuccessful ageing: a study in Alzheimer's disease patients from Northern Italy. Mech Ageing Dev 2003;124:525-8.
14. Guerreiro RJ, Bras JM, Santana I, Januario C, Santiago B, Morgadinho AS, Ribeiro MH, Hardy J, Singleton A, Oliveira C. Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol 2006;6:24.
15. Kauwe JS, Bertelsen S, Mayo K, Cruchaga C, Abraham R, Hollingworth P, Harold D, Owen MJ, Williams J, Lovestone S, Morris JC, Goate AM. Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2010;153B:955-9.
16. Moalem S, Percy ME, Andrews DF, Kruck TP, Wong S, Dalton AJ, Mehta P, Fedor B, Warren AC. Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet 2000;93:58-66.
17. Gibb WR. Accuracy in the clinical diagnosis of parkinsonian syndromes. Postgrad Med J 1988;64:345-51.
18. Wolf PL. Ceruloplasmin: methods and clinical use. Crit Rev Clin Lab Sci 1982;17:229-45.
19. Siotto M, Pasqualetti P, Marano M, Squitti R. Automation of o- dianisidine assay for ceruloplasmin activity analyses: usefulness of investigation in Wilson's disease and in hepatic encephalopathy. J Neural Transm 2014;121:1281-6.
20. Higgins T. Novel chromogen for serum iron determinations. Clin Chem 1981;27:1619-20.
21. Skikne BS, Flowers CH, Cook JD. Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood 1990;75:1870-6.
22. Simo JM, Joven J, Cliville X, Sans T. Automated latex agglutination immunoassay of serum ferritin with a centrifugal analyzer. Clin Chem 1994;40:625-9.
23. Farhoudi M, Taheraghdam A, Farid GA, Talebi M, Pashapou A, Majidi J, Goldust M. Serum iron and ferritin level in idiopathic Parkinson. Pak J Biol Sci 2012;15:1094-7.
24. Madenci G, Bilen S, Arli B, Saka M, Ak F. Serum iron, vitamin B12 and folic acid levels in Parkinson's disease. Neurochem Res 2012;37:1436-41.
25. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981;1:1293-4.
26. Sullivan JL. Stored iron and ischemic heart disease. Empirical support for a new paradigm. Circulation 1992;86:1036-7.
27. Berge LN, Bonaa KH, Nordoy A. Serum ferritin, sex hormones, and cardiovascular risk factors in healthy women. Arteriosclerosis Thromb 1994;14:857-61.
28. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 1997;96:3300-7.
29. Zacharski LR, Chow B, Lavori PW, Howes PS, Bell MR, DiTommaso MA, Carnegie NM, Bech F, Amidi M, Muluk S. The iron (Fe) and atherosclerosis study (FeAST): a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease. Am Heart J 2000;139:337-45.
30. Hong D, Kim YS, Son ES, Kim KN, Kim BT, Lee DJ, Kim KM. Total testosterone and sex hormone-binding globulin are associated with metabolic syndrome independent of age and body mass index in Korean men. Maturitas 2013;74:148-53.
31. Waalen J, von Lohneysen K, Lee P, Xu X, Friedman JS. Erythropoietin, GDF15, IL6, hepcidin and testosterone levels in a large cohort of elderly individuals with anaemia of known and unknown cause. Eur J Haematol 2011;87:107-16.
32. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Salonen R, Rauramaa R, Salonen JT. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol/Eur Fed Endocr Soc 2003;149:601-8.
33. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97:2050-8.
34. Liu Z, Ye F, Zhang H, Gao Y, Tan A, Zhang S, Xiao Q, Zhang B, Huang L, Ye B, Qin X, Wu C, Lu Z, Zhang Y, Liao M, Yang X, Mo Z. The association between the levels of serum ferritin and sex hormones in a large scale of Chinese male population. PLOS One 2013;8:e75908.
35. Wachnik A, Biro G, Biro L, Korom M, Gergely A, Antal M. Effect of sex hormones on copper, zinc, iron nutritional status and hepatic lipid peroxidation in rats. Die Nahrung 1993;37:28-34.
36. Hou Y, Zhang S, Wang L, Li J, Qu G, He J, Rong H, Ji H, Liu S. Estrogen regulates iron homeostasis through governing hepatic hepcidin expression via an estrogen response element. Gene 2012;511:398-403.
37. Pichler I, Del Greco MF, Gogele M, Lill CM, Bertram L, Do CB, Eriksson N, Foroud T, Myers RH, Consortium PG, Nalls M, Keller MF, International Parkinson's Disease Genomics C, Wellcome Trust Case Control C, Benyamin B, Whitfield JB, Genetics of Iron Status C, Pramstaller PP, Hicks AA, Thompson JR, Minelli C. Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. PLOS Med 2013;10:e1001462.